BIOMAT Database Logo BIOMAT Database Logo

Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma). 1991

W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Third Department of Medicine, Johannes Gutenberg University, Mainz, Germany.

In order to investigate serum levels of soluble HLA class I antigens after single injection of various doses of recombinant IFN-gamma (rIFN-gamma) and to correlate the changes observed to beta-2-microglobulin serum levels, we studied five patients with metastasizing renal cell carcinoma. Each patient received three treatment cycles of 10, 100 and 500 micrograms rIFN-gamma three times at weekly intervals. The treatment cycles were separated by a therapy-free interval of 2 weeks. The order of dose levels was randomly assigned to each patient. Serum levels of soluble HLA class I proteins were measured by an ELISA in samples drawn immediately before and 4, 24, 48, 72 and 168 h after each administration of rIFN-gamma. Beta-2-microglobulin was assessed in parallel using a commercially available radioimmunoassay. Significant induction of soluble HLA class I protein serum levels was observed after treatment with 100 and 500 micrograms rIFN-gamma. The increments peaked after 2-4 days and remained elevated for up to more than 7 days. A significant correlation between increments of soluble HLA class I proteins and beta-2-microglobulin was observed. We conclude that measurement of soluble HLA serum levels is practical for monitoring induction of HLA class I synthesis in patients treated with rIFN-gamma. The correlation observed between induction of beta-2-microglobulin and soluble HLA class I proteins indicates that measurement of beta-2-microglobulin might be sufficient for the biological response monitoring in clinical studies.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002292 Carcinoma, Renal Cell A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. Adenocarcinoma, Renal Cell,Carcinoma, Hypernephroid,Grawitz Tumor,Hypernephroma,Renal Carcinoma,Adenocarcinoma Of Kidney,Adenocarcinoma, Renal,Chromophil Renal Cell Carcinoma,Chromophobe Renal Cell Carcinoma,Clear Cell Renal Carcinoma,Clear Cell Renal Cell Carcinoma,Collecting Duct Carcinoma,Collecting Duct Carcinoma (Kidney),Collecting Duct Carcinoma of the Kidney,Nephroid Carcinoma,Papillary Renal Cell Carcinoma,Renal Cell Cancer,Renal Cell Carcinoma,Renal Cell Carcinoma, Papillary,Renal Collecting Duct Carcinoma,Sarcomatoid Renal Cell Carcinoma,Adenocarcinoma Of Kidneys,Adenocarcinomas, Renal Cell,Cancer, Renal Cell,Carcinoma, Collecting Duct,Carcinoma, Collecting Duct (Kidney),Carcinoma, Nephroid,Carcinoma, Renal,Carcinomas, Collecting Duct,Carcinomas, Collecting Duct (Kidney),Carcinomas, Renal Cell,Collecting Duct Carcinomas,Collecting Duct Carcinomas (Kidney),Hypernephroid Carcinoma,Hypernephroid Carcinomas,Hypernephromas,Kidney, Adenocarcinoma Of,Nephroid Carcinomas,Renal Adenocarcinoma,Renal Adenocarcinomas,Renal Carcinomas,Renal Cell Adenocarcinoma,Renal Cell Adenocarcinomas,Renal Cell Cancers,Renal Cell Carcinomas,Tumor, Grawitz
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001613 beta 2-Microglobulin An 11-kDa protein associated with the outer membrane of many cells including LYMPHOCYTES. It is the small subunit of MHC CLASS I MOLECULES. Association with beta 2-microglobulin is generally required for the transport of class I heavy chains from the endoplasmic reticulum to the cell surface. Beta 2-microglobulin is present in small amounts in serum, CEREBROSPINAL FLUID, and urine of healthy individuals, and to a much greater degree in the urine and plasma of patients with tubular PROTEINURIA, renal failure, or kidney transplants. Thymotaxin,beta 2 Microglobulin
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Production of soluble HLA-class-I molecules by IFN-gamma-induced colon-adenocarcinoma cells.
February 1995, International journal of cancer,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Enhanced expression of HLA class I molecules in human hepatocellular carcinoma cells transduced with gamma-interferon gene.
April 1998, Chinese medical journal,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
IFN-gamma production in human NK cells through the engagement of CD8 by soluble or surface HLA class I molecules.
November 2003, European journal of immunology,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Alternative splicing of HLA class I transcripts induced by IFN-gamma and TNF in fibroblasts: release of soluble HLA class I heavy chain and an associate protein.
April 1995, Cellular immunology,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Soluble HLA class I antigen secretion by normal lymphocytes: relationship with cell activation and effect of interferon-gamma.
November 1990, Clinical and experimental immunology,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Decreased levels of serum soluble HLA class I antigens in HLA-B27 positive spondyloarthropathies.
February 2006, Annals of the rheumatic diseases,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Soluble HLA-DR molecules in patients with HLA class II versus class I associated disorders.
January 1991, Autoimmunity,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Translational control of MHC class II I-A molecules by IFN-gamma.
August 1998, Journal of immunology (Baltimore, Md. : 1950),
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Association of serum concentration of soluble class I HLA with HLA allotypes.
March 1996, Transplantation,
W E Aulitzky, and H Grosse-Wilde, and U Westhoff, and H Tilg, and W Aulitzky, and G Gastl, and M Herold, and C Huber
Biochemical complexity of serum HLA class I molecules.
January 1988, Immunogenetics,
Copied contents to your clipboard!